Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/03/19 | $51,000,000 | Series A |
Adams Street Partners NanoDimension Qiming Venture Partners  Sanofi Ventures | undisclosed |
| 04/07/21 | $100,000,000 | Series B |
Adams Street Partners Cormorant Asset Management Janus Henderson Investors ND Capital Omega Funds Open Philanthropy Project Perceptive Advisors Qiming Venture Partners RA Capital Management Sanofi Ventures Surveyor Capital Viking Global Investors | undisclosed |
